INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1501, 21547, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1502, 21551, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1503, 21655, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1504, 21656, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1505, 26675, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1506, 29352, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1507, 29353, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1508, 33077, 'Lactulose', 'Diabetes Mellitus', 'Since lactulose solution contains galactose and lactose, it should be used cautiously in patients with diabetes.', '2', '"Product Information. Chronulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Cephulac (lactulose)." Hoechst Marion Roussel  (2002):|"Product Information. Duphalac (lactulose)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Enulose (lactulose)." United Research Laboratories/Mutual Pharmaceutical Company  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1509, 7076, 'Lamivudine', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1510, 7077, 'Lamivudine', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1511, 12792, 'Lamivudine', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1512, 29612, 'Lamivudine', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1513, 7076, 'Lamivudine', 'Pancreatitis', 'The reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), stavudine (d4T) and lamivudine (3TC), may cause pancreatitis.  The incidence is generally low but is approximately 7% with ddI, and up to 15% in pediatric patients given 3TC.  Patients with a history of or known risk factors for pancreatitis, such as alcohol abuse or hypertriglyceridemia, should be monitored closely during therapy with these agents.  Therapy should be discontinued at the first signs or symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.', '3', 'Shelton MJ, O''Donnell AM, Morse GD "Didanosine." Ann Pharmacother 26 (1992):  660-70|Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Bouvet E, Casalino E, Prevost MH, Vachon F "Fatal case of 2'',3''-dideoxyinosine-associated pancreatitis." Lancet 336 (1990):  1515|Maxson CJ, Greenfield SM, Turner JL "Acute pancreatitis as a common complication of 2'',3''-dideoxyinosine therapy in the acquired immunodeficiency syndrome." Am J Gastroenterol 87 (1992):  708-13|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, Barbhaiya RH, Pittman KA, Dolin R, Valentine FT, "Analysis of potential risk factors associated with the development of pancreatitis in phase i patients with AIDS or AIDS-related complex receiving didanosine." J Infect Dis 169 (1994):  1250-5|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L "Rates and risk factors for adverse events associated with didanosine in the expanded access program." Clin Infect Dis 19 (1994):  1076-83|van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, Jonker P, Danner SA "The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study." AIDS 6 (1992):  1471-5|van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al. "Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study." J Infect Dis 171 (1995):  1166-71|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1514, 7077, 'Lamivudine', 'Pancreatitis', 'The reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), stavudine (d4T) and lamivudine (3TC), may cause pancreatitis.  The incidence is generally low but is approximately 7% with ddI, and up to 15% in pediatric patients given 3TC.  Patients with a history of or known risk factors for pancreatitis, such as alcohol abuse or hypertriglyceridemia, should be monitored closely during therapy with these agents.  Therapy should be discontinued at the first signs or symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.', '3', 'Shelton MJ, O''Donnell AM, Morse GD "Didanosine." Ann Pharmacother 26 (1992):  660-70|Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Bouvet E, Casalino E, Prevost MH, Vachon F "Fatal case of 2'',3''-dideoxyinosine-associated pancreatitis." Lancet 336 (1990):  1515|Maxson CJ, Greenfield SM, Turner JL "Acute pancreatitis as a common complication of 2'',3''-dideoxyinosine therapy in the acquired immunodeficiency syndrome." Am J Gastroenterol 87 (1992):  708-13|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, Barbhaiya RH, Pittman KA, Dolin R, Valentine FT, "Analysis of potential risk factors associated with the development of pancreatitis in phase i patients with AIDS or AIDS-related complex receiving didanosine." J Infect Dis 169 (1994):  1250-5|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L "Rates and risk factors for adverse events associated with didanosine in the expanded access program." Clin Infect Dis 19 (1994):  1076-83|van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, Jonker P, Danner SA "The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study." AIDS 6 (1992):  1471-5|van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al. "Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study." J Infect Dis 171 (1995):  1166-71|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1515, 12792, 'Lamivudine', 'Pancreatitis', 'The reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), stavudine (d4T) and lamivudine (3TC), may cause pancreatitis.  The incidence is generally low but is approximately 7% with ddI, and up to 15% in pediatric patients given 3TC.  Patients with a history of or known risk factors for pancreatitis, such as alcohol abuse or hypertriglyceridemia, should be monitored closely during therapy with these agents.  Therapy should be discontinued at the first signs or symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.', '3', 'Shelton MJ, O''Donnell AM, Morse GD "Didanosine." Ann Pharmacother 26 (1992):  660-70|Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Bouvet E, Casalino E, Prevost MH, Vachon F "Fatal case of 2'',3''-dideoxyinosine-associated pancreatitis." Lancet 336 (1990):  1515|Maxson CJ, Greenfield SM, Turner JL "Acute pancreatitis as a common complication of 2'',3''-dideoxyinosine therapy in the acquired immunodeficiency syndrome." Am J Gastroenterol 87 (1992):  708-13|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, Barbhaiya RH, Pittman KA, Dolin R, Valentine FT, "Analysis of potential risk factors associated with the development of pancreatitis in phase i patients with AIDS or AIDS-related complex receiving didanosine." J Infect Dis 169 (1994):  1250-5|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L "Rates and risk factors for adverse events associated with didanosine in the expanded access program." Clin Infect Dis 19 (1994):  1076-83|van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, Jonker P, Danner SA "The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study." AIDS 6 (1992):  1471-5|van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al. "Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study." J Infect Dis 171 (1995):  1166-71|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1516, 29612, 'Lamivudine', 'Pancreatitis', 'The reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), stavudine (d4T) and lamivudine (3TC), may cause pancreatitis.  The incidence is generally low but is approximately 7% with ddI, and up to 15% in pediatric patients given 3TC.  Patients with a history of or known risk factors for pancreatitis, such as alcohol abuse or hypertriglyceridemia, should be monitored closely during therapy with these agents.  Therapy should be discontinued at the first signs or symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.', '3', 'Shelton MJ, O''Donnell AM, Morse GD "Didanosine." Ann Pharmacother 26 (1992):  660-70|Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Bouvet E, Casalino E, Prevost MH, Vachon F "Fatal case of 2'',3''-dideoxyinosine-associated pancreatitis." Lancet 336 (1990):  1515|Maxson CJ, Greenfield SM, Turner JL "Acute pancreatitis as a common complication of 2'',3''-dideoxyinosine therapy in the acquired immunodeficiency syndrome." Am J Gastroenterol 87 (1992):  708-13|Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992):  656-83|Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991):  419-49|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, Barbhaiya RH, Pittman KA, Dolin R, Valentine FT, "Analysis of potential risk factors associated with the development of pancreatitis in phase i patients with AIDS or AIDS-related complex receiving didanosine." J Infect Dis 169 (1994):  1250-5|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L "Rates and risk factors for adverse events associated with didanosine in the expanded access program." Clin Infect Dis 19 (1994):  1076-83|van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, Jonker P, Danner SA "The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study." AIDS 6 (1992):  1471-5|van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al. "Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study." J Infect Dis 171 (1995):  1166-71|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996):  34-40', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1517, 7076, 'Lamivudine', 'Kidney Diseases', 'Patients with clinically significant renal impairment may be at greater risk for toxicities and adverse effects from nucleoside reverse transcriptase inhibitors (NRTIs) due to decreased drug clearance.  Dosage adjustments are recommended.  In addition, these patients should be monitored closely during NRTI therapy, and dosages adjusted further if necessary.', '3', '"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1518, 7077, 'Lamivudine', 'Kidney Diseases', 'Patients with clinically significant renal impairment may be at greater risk for toxicities and adverse effects from nucleoside reverse transcriptase inhibitors (NRTIs) due to decreased drug clearance.  Dosage adjustments are recommended.  In addition, these patients should be monitored closely during NRTI therapy, and dosages adjusted further if necessary.', '3', '"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1519, 12792, 'Lamivudine', 'Kidney Diseases', 'Patients with clinically significant renal impairment may be at greater risk for toxicities and adverse effects from nucleoside reverse transcriptase inhibitors (NRTIs) due to decreased drug clearance.  Dosage adjustments are recommended.  In addition, these patients should be monitored closely during NRTI therapy, and dosages adjusted further if necessary.', '3', '"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1520, 29612, 'Lamivudine', 'Kidney Diseases', 'Patients with clinically significant renal impairment may be at greater risk for toxicities and adverse effects from nucleoside reverse transcriptase inhibitors (NRTIs) due to decreased drug clearance.  Dosage adjustments are recommended.  In addition, these patients should be monitored closely during NRTI therapy, and dosages adjusted further if necessary.', '3', '"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|"Product Information. Zerit (stavudine)." Bristol-Myers Squibb  (2001):|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1521, 0, 'Lanreotide', 'Hepatic Insufficiency', 'In clinical trials, a reduced clearance of lanreotide was observed in subjects with moderate to severe hepatic impairment.  Patients with moderate to severe hepatic impairment should begin treatment with lanreotide 60 mg.  Caution should be exercised when using this agent in patients with moderate or severe hepatic impairment for an extended dosing interval.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1522, 0, 'Lanreotide', 'Kidney Diseases', 'Lanreotide has not been studied in patients with mild, moderate and severe renal failure.  It is recommended to start patients with moderate and severe renal impairment at a lower dose as clinically appropriate.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1523, 0, 'Lanreotide', 'Hypothyroidism', 'Slight decreases in thyroid function have been seen during treatment with lanreotide.  Care should be taken when using this agent in patients with thyroid dysfunctions and it is recommended to monitor thyroid function where clinically indicated.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1524, 0, 'Lanreotide', 'Adrenal Insufficiency', 'Treatment with somatostatin analogs may suppress the pituitary hormones other than GH/IGF-1.  It is recommended to monitor pituitary function prior to initiation of therapy and periodically during treatment, as clinically appropriate.  Patients should be monitored for and instructed on the signs and symptoms of adrenal insufficiency during therapy.  If adrenal insufficiency is suspected it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1525, 0, 'Lanreotide', 'Bradycardia', 'Bradycardia has been reported with the use of somatostatin analogs.  It is recommended to carefully monitor patients with cardiac disorders for the development of bradycardia.  Dose adjustments of beta-blockers, calcium channel blockers, or correction of electrolyte disturbances may be necessary.  Care should be taken when initiating treatment with these agents in patients with bradycardia.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1526, 0, 'Lanreotide', 'Cholelithiasis', 'Somatostatin analogs may reduce gallbladder motility and lead to gallstones formation.  It is recommended to assess the gallbladder prior to starting therapy and periodically thereafter.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1527, 0, 'Lanreotide', 'Diabetes Mellitus', 'Elevations in blood glucose levels have been reported with the use of somatostatin analogs.  Cushing''s disease patients with poor glycemic control may be at a higher risk of developing severe hyperglycemia and associated complications, e.g., ketoacidosis.  It is recommended to assess the glycemic status of hemoglobin A1C prior to starting treatment with these agents.  Self-monitoring of blood glucose and/or FPG assessments should be done every week for the first two to three months and periodically thereafter, as clinically appropriate, as well as over the first two to four weeks after any dose increase.  If uncontrolled hyperglycemia persists, despite appropriate medical management, the dose of these agents should be reduced or discontinued.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1528, 0, 'Laronidase', 'Heart Diseases', 'Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions during laronidase therapy and require additional monitoring.  Patients with compromised respiratory function or acute febrile or respiratory illness at the time of laronidase infusion may be at higher risk of life-threatening complications from hypersensitivity reactions.  Careful consideration should be given to the patient''s clinical status before laronidase administration and delaying the laronidase infusion should be considered.Caution is recommended when administering laronidase to patients susceptible to fluid overload, or patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function for whom fluid restriction is indicated; these patients may be at risk of serious exacerbation of their cardiac or respiratory status during infusions.  Appropriate medical support and monitoring measures should be readily available during laronidase infusion, and some patients may require prolonged observation times that should be based on the needs of each patient.', '3', '"Product Information. Aldurazyme (laronidase)." Genzyme Corporation  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1529, 21596, 'Lanthanum carbonate', 'Ileus', 'The use of lanthanum carbonate is contraindicated in patients with bowel obstruction, including ileus and fecal impaction.', '3', '"Product Information. Fosrenol (lanthanum carbonate)." Shire US Inc  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1530, 21596, 'Lanthanum carbonate', 'Gastrointestinal Diseases', 'Serious cases of gastrointestinal obstruction and perforation have been reported in patients taking lanthanum, some requiring surgery and hospitalization.  Risk factors identified from post marketing reports include altered gastrointestinal anatomy (diverticular disease, peritonitis, history of GI surgery, ulceration or cancer), hypomotility disorders, and some concomitant medications as calcium channel blockers.  However, some cases have also been reported in patients with no history of gastrointestinal disease.  Lanthanum should be used cautiously in patients with gastrointestinal disease.', '2', '"Product Information. Fosrenol (lanthanum carbonate)." Shire US Inc  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1531, 11771, 'Lapatinib', 'Cardiomyopathies', 'Cardiomyopathy was observed in clinical trials of certain EGFR inhibitors.  Assess Left Ventricular Ejection Fraction (LVEF) by echocardiogram or multigated acquisition (MUGA) scan before initiation of these agents and then at 3 month intervals while on treatment.  Caution is recommended when prescribing these agents to patients with conditions that could impair left ventricular function and it is recommended to withhold treatment with these agents if ejection fraction drops below the established lower limit of normal.  For symptomatic congestive heart failure or persistent, asymptomatic LV dysfunction that does not resolve within 4 weeks, permanently discontinue these agents.', '3', '"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1532, 11771, 'Lapatinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of EGFR inhibitors.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving these agents for the development of inflammatory or infectious sequelae.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of these agents for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications.  Advise patients to wear sunscreen and hats and limit sun exposure while receiving therapy with these agents as exposure to sunlight can exacerbate dermatologic toxicities.', '3', '"Product Information. Iressa (gefitinib)." Astra-Zeneca Pharmaceuticals  (2003):|"Product Information. Erbitux (cetuximab)." Bristol-Myers Squibb  (2004):|"Product Information. Tarceva (erlotinib)." Genentech  (2004):|"Product Information. Vectibix (panitumumab)." Amgen USA  (2006):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals  (2015):|"Product Information. Portrazza (necitumumab)." Eli Lilly and Company  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1533, 11771, 'Lapatinib', 'Lung Diseases', 'The use of certain EGFR inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.', '3', '"Product Information. Iressa (gefitinib)." Astra-Zeneca Pharmaceuticals  (2003):|"Product Information. Erbitux (cetuximab)." Bristol-Myers Squibb  (2004):|"Product Information. Tarceva (erlotinib)." Genentech  (2004):|"Product Information. Vectibix (panitumumab)." Amgen USA  (2006):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1534, 11771, 'Lapatinib', 'Long QT Syndrome', 'QT prolongation was observed in patients treated with certain EGFR inhibitors.  These agents should be administered with caution in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval.  Serum electrolytes should be corrected prior to initiating therapy with these agents.  Periodic monitoring of ECGs and electrolytes is recommended in these patients.  Permanently discontinue the use of these agents in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia.', '3', '"Product Information. Erbitux (cetuximab)." Bristol-Myers Squibb  (2004):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1535, 11771, 'Lapatinib', 'Liver Diseases', 'Lapatinib undergoes extensive metabolism in the liver.  Hepatotoxicity has been associated with the use of lapatinib and it may be severe and fatal.  The hepatotoxicity may occur days to several months after initiation of treatment.  Therapy with lapatinib should be administered cautiously in patients with severe hepatic impairment and a dose reduction should be considered for patients with severe pre-existing hepatic impairment.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended before initiation of treatment, every 4 to 6 weeks during treatment, and as clinically indicated.  In patients who develop severe hepatotoxicity while on therapy, lapatinib should be discontinued and patients should not be retreated.', '3', '"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1536, 11771, 'Lapatinib', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1537, 11771, 'Lapatinib', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '"Product Information. Herceptin (trastuzumab)." Genentech  (2001):|"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Perjeta (pertuzumab)." Genentech  (2012):|"Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech  (2022):|"Product Information. Margenza (margetuximab)." Almirall  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1538, 11771, 'Lapatinib', 'Kidney Diseases', 'Lapatinib pharmacokinetics have not been specifically studied in patients with renal impairment or in patients undergoing hemodialysis.  Close monitoring is recommended.', '2', '"Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1539, 0, 'Larotrectinib', 'Liver Failure', 'Forty- five percent of the patients receiving larotrectinib had increased hepatic parameters, including Grade 3 increased AST or ALT in 6% of patients.  Monitor liver tests, including ALT and AST, every 2 weeks during the first month of treatment, then monthly thereafter, and as clinically indicated.  Treatment should be withheld or permanently discontinued based on the severity of hepatic toxicity.  Caution is advised in patients with moderate to severe hepatic impairment as the drug clearance was reduced in these patients (Child-Pugh B and C).  Dose should be reduced on these patients as recommended by the manufacturers (refer to prescribing information).', '2', '"Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1540, 0, 'Lasmiditan', 'Liver Diseases', 'The use of lasmiditan is not recommended in patients with severe hepatic impairment.  No dosage adjustment is needed for patients with mild or moderate hepatic impairment.', '3', '"Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1541, 0, 'Lasmiditan', 'Respiratory Insufficiency', 'The use of lasmiditan may cause central nervous system (CNS) depression, including dizziness and sedation.  Because of the potential for lasmiditan to cause sedation, other cognitive or neuropsychiatric adverse reactions, and driving impairment, this agent should be used with caution if used in combination with alcohol or other CNS depressants.  It is recommended to evaluate patients for risk of CNS depression and patients should be warned against engaging in potentially hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery, for at least 8 hours after lasmiditan is taken.  Patients who cannot follow this recommendation should not take lasmiditan.', '2', '"Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1542, 0, 'Lasmiditan', 'Substance-Related Disorders', 'The use of lasmiditan has the potential to cause abuse.  It is recommended to evaluate patients for risk of drug abuse and observe them for signs of lasmiditan misuse or abuse.  Drug dependence was not observed in healthy subjects following abrupt cessation after 7 daily doses of lasmiditan 200 mg or 400 mg.', '2', '"Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1543, 0, 'Lasmiditan', 'Serotonin Syndrome', 'The use of lasmiditan has been associated with reactions consistent with serotonin syndrome.  Serotonin syndrome may also occur with lasmiditan during coadministration with serotonergic drugs.  The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication.  It is recommended to discontinue therapy if serotonin syndrome is suspected.', '2', '"Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1544, 120, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1545, 5357, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1546, 6616, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1547, 7105, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1548, 9757, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1549, 21590, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1550, 21595, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1551, 21606, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1552, 21607, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1553, 21609, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1554, 21610, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1555, 22020, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1556, 22025, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1557, 24719, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1558, 29826, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1559, 30012, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1560, 30013, 'Lansoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1561, 120, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1562, 5357, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1563, 6616, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1564, 7105, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1565, 9757, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1566, 21590, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1567, 21595, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1568, 21606, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1569, 21607, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1570, 21609, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1571, 21610, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1572, 22020, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1573, 22025, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1574, 24719, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1575, 29826, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1576, 30012, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1577, 30013, 'Lansoprazole', 'Liver Diseases', 'Lansoprazole is primarily metabolized by the liver.  Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.', '2', 'Spencer CM, Faulds D "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs 48 (1994):  404-30|Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol 45 (1993):  367-71|Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol 47 (1995):  410-8|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1578, 120, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1579, 5357, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1580, 6616, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1581, 7105, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1582, 9757, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1583, 21590, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1584, 21595, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1585, 21606, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1586, 21607, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1587, 21609, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1588, 21610, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1589, 22020, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1590, 22025, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1591, 24719, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1592, 29826, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1593, 30012, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1594, 30013, 'Lansoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1595, 120, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1596, 5357, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1597, 6616, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1598, 7105, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1599, 9757, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1600, 21590, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1601, 21595, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1602, 21606, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1603, 21607, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1604, 21609, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1605, 21610, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1606, 22020, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1607, 22025, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1608, 24719, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1609, 29826, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1610, 30012, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1611, 30013, 'Lansoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1612, 832, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1613, 978, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1614, 979, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1615, 1149, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1616, 1150, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1617, 1151, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1618, 7176, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1619, 12066, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1620, 13039, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1621, 21678, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1622, 21679, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1623, 25621, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1624, 25622, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1625, 28954, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1626, 28955, 'Leflunomide', 'IMMUNE SUPPRESSION', 'Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide.  Leflunomide is an immunomodulatory agent with antiproliferative activity.  The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression.  Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality.  It is recommended to monitor blood levels at baseline and regularly during the course of therapy.  If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1627, 832, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1628, 978, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1629, 979, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1630, 1149, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1631, 1150, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1632, 1151, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1633, 7176, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1634, 12066, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1635, 13039, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1636, 21678, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1637, 21679, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1638, 25621, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1639, 25622, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1640, 28954, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1641, 28955, 'Leflunomide', 'Liver Diseases', 'Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide.  Leflunomide is contraindicated in patients with severe hepatic impairment.  Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST.  Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment.  Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity.  Therapy with leflunomide is not recommended in patients with preexisting liver disease.  Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1642, 832, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1643, 978, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1644, 979, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1645, 1149, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1646, 1150, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1647, 1151, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1648, 7176, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1649, 12066, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1650, 13039, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1651, 21678, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1652, 21679, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1653, 25621, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1654, 25622, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1655, 28954, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1656, 28955, 'Leflunomide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported during leflunomide therapy.  Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy.  Therapy with leflunomide should be administered cautiously in these patients.  Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1657, 832, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1658, 978, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1659, 979, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1660, 1149, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1661, 1150, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1662, 1151, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1663, 7176, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1664, 12066, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1665, 13039, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1666, 21678, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1667, 21679, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1668, 25621, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1669, 25622, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1670, 28954, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1671, 28955, 'Leflunomide', 'Lung Diseases', 'The use of leflunomide has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported.  Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever.  If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1672, 832, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1673, 978, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1674, 979, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1675, 1149, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1676, 1150, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1677, 1151, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1678, 7176, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1679, 12066, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1680, 13039, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1681, 21678, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1682, 21679, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1683, 25621, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1684, 25622, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1685, 28954, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1686, 28955, 'Leflunomide', 'Kidney Diseases', 'The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment.  Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1687, 832, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1688, 978, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1689, 979, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1690, 1149, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1691, 1150, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1692, 1151, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1693, 7176, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1694, 12066, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1695, 13039, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1696, 21678, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1697, 21679, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1698, 25621, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1699, 25622, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1700, 28954, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1701, 28955, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1702, 832, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1703, 978, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1704, 979, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1705, 1149, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1706, 1150, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1707, 1151, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1708, 7176, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1709, 12066, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1710, 13039, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1711, 21678, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1712, 21679, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1713, 25621, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1714, 25622, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1715, 28954, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1716, 28955, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '"Product Information. Arava (leflunomide)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1717, 6419, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1718, 20659, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1719, 20660, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1720, 20661, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1721, 20662, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1722, 20903, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1723, 20904, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1724, 20905, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1725, 29800, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1726, 30582, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1727, 30583, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1728, 6419, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1729, 20659, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1730, 20660, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1731, 20661, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1732, 20662, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1733, 20903, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1734, 20904, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1735, 20905, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1736, 29800, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1737, 30582, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1738, 30583, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '"Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1739, 0, 'Lemborexant', 'Alcoholism', 'Patients treated with lemborexant should not consume alcohol as it can increase drowsiness and also the incidence of adverse effects.', '2', '"Product Information. Dayvigo (lemborexant)." Eisai Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1740, 0, 'Lemborexant', 'Pulmonary Disease, Chronic Obstructive', 'Lemborexant has not been studied in patients with moderate to severe obstructive sleep apnea (OSA) or in patients with chronic obstructive pulmonary disease.  Caution is advised if prescribing to patients with compromised respiratory function.', '2', '"Product Information. Dayvigo (lemborexant)." Eisai Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1741, 0, 'Lemborexant', 'Depressive Disorder', 'Worsening of depression and suicidal thoughts and actions have been reported with the use of lemborexant.  Caution is advised in patients with depression.  Protective measures may be required in patients with suicidal tendencies, including prescription of the lowest number of tablets at one time.', '2', '"Product Information. Dayvigo (lemborexant)." Eisai Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1742, 0, 'Lemborexant', 'Liver Failure', 'Lemborexant has not been studied in patients with severe liver dysfunction (Child-Pugh Class C).  Its use is not recommended in these patients.', '2', '"Product Information. Dayvigo (lemborexant)." Eisai Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1743, 6227, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1744, 20747, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1745, 20748, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1746, 21694, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1747, 21695, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1748, 25971, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1749, 25972, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1750, 25973, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1751, 6227, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1752, 20747, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1753, 20748, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1754, 21694, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1755, 21695, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1756, 25971, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1757, 25972, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1758, 25973, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1759, 6227, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '"Product Information. Vidaza (azacitidine)." Celgene Corporation  (2004):|"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1760, 20747, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '"Product Information. Vidaza (azacitidine)." Celgene Corporation  (2004):|"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1761, 20748, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '"Product Information. Vidaza (azacitidine)." Celgene Corporation  (2004):|"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1762, 21694, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '"Product Information. Vidaza (azacitidine)." Celgene Corporation  (2004):|"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1763, 21695, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '"Product Information. Vidaza (azacitidine)." Celgene Corporation  (2004):|"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1764, 25971, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '"Product Information. Vidaza (azacitidine)." Celgene Corporation  (2004):|"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1765, 25972, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '"Product Information. Vidaza (azacitidine)." Celgene Corporation  (2004):|"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1766, 25973, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '"Product Information. Vidaza (azacitidine)." Celgene Corporation  (2004):|"Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1767, 314, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1768, 4048, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1769, 4777, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1770, 7215, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1771, 12699, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1772, 18918, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1773, 21721, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1774, 21723, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1775, 32443, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1776, 314, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1777, 4048, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1778, 4777, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1779, 7215, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1780, 12699, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1781, 18918, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1782, 21721, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1783, 21723, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1784, 32443, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1785, 314, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1786, 4048, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1787, 4777, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1788, 7215, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1789, 12699, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1790, 18918, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1791, 21721, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1792, 21723, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1793, 32443, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '"Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1794, 21700, 'Lenvatinib', 'Thromboembolism', 'In clinical trials, arterial thromboembolic events were reported in patients treated with lenvatinib.  It is recommended to discontinue lenvatinib following an arterial thrombotic event.  Care should be exercised when resuming lenvatinib after an arterial thromboembolic event as its safety has not been established and its use has not been studied in patients who have had an arterial thromboembolic event within the previous 6 months.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1795, 21701, 'Lenvatinib', 'Thromboembolism', 'In clinical trials, arterial thromboembolic events were reported in patients treated with lenvatinib.  It is recommended to discontinue lenvatinib following an arterial thrombotic event.  Care should be exercised when resuming lenvatinib after an arterial thromboembolic event as its safety has not been established and its use has not been studied in patients who have had an arterial thromboembolic event within the previous 6 months.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1796, 21700, 'Lenvatinib', 'Hemorrhage', 'Hemorrhagic events, including fatal hemorrhagic events have been reported with the use of lenvatinib.  It is recommended to withhold treatment and to either resume at a reduced dose or discontinue treatment depending on the severity and persistence of hemorrhage.  Discontinue therapy in patients who experience severe or fatal hemorrhagic events.  Prior to initiating treatment, consider the risk of severe or fatal hemorrhage associated with tumor invasion/infiltration of major blood vessels (e.g.  carotid artery).', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1797, 21701, 'Lenvatinib', 'Hemorrhage', 'Hemorrhagic events, including fatal hemorrhagic events have been reported with the use of lenvatinib.  It is recommended to withhold treatment and to either resume at a reduced dose or discontinue treatment depending on the severity and persistence of hemorrhage.  Discontinue therapy in patients who experience severe or fatal hemorrhagic events.  Prior to initiating treatment, consider the risk of severe or fatal hemorrhage associated with tumor invasion/infiltration of major blood vessels (e.g.  carotid artery).', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1798, 21700, 'Lenvatinib', 'Heart Failure', 'Cardiac dysfunctions, defined as decreased left or right ventricular function, cardiac failure, or pulmonary edema have been reported with the use of lenvatinib.  It is recommended to monitor patients for clinical symptoms or signs of cardiac decompensation.  Withhold lenvatinib therapy for development of Grade 3 cardiac dysfunction until improved and either resume at a reduced dose or discontinue its use depending on the severity and persistence of cardiac dysfunction.  Discontinue lenvatinib for Grade 4 cardiac dysfunction.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1799, 21701, 'Lenvatinib', 'Heart Failure', 'Cardiac dysfunctions, defined as decreased left or right ventricular function, cardiac failure, or pulmonary edema have been reported with the use of lenvatinib.  It is recommended to monitor patients for clinical symptoms or signs of cardiac decompensation.  Withhold lenvatinib therapy for development of Grade 3 cardiac dysfunction until improved and either resume at a reduced dose or discontinue its use depending on the severity and persistence of cardiac dysfunction.  Discontinue lenvatinib for Grade 4 cardiac dysfunction.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1800, 21700, 'Lenvatinib', 'Diarrhea', 'Cases of diarrhea have been reported with the use of lenvatinib, sometimes leading to interruption of therapy.  It is recommended to initiate prompt medical management for the development of diarrhea and to monitor for dehydration.  It might be necessary to interrupt treatment with lenvatinib or resume at a reduced dose or permanently discontinue treatment with lenvatinib if severe or fatal diarrhea persists despite medical management.  Care and close monitoring is recommended when using this agent in patients presenting diarrhea or at risk of developing diarrhea.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1801, 21701, 'Lenvatinib', 'Diarrhea', 'Cases of diarrhea have been reported with the use of lenvatinib, sometimes leading to interruption of therapy.  It is recommended to initiate prompt medical management for the development of diarrhea and to monitor for dehydration.  It might be necessary to interrupt treatment with lenvatinib or resume at a reduced dose or permanently discontinue treatment with lenvatinib if severe or fatal diarrhea persists despite medical management.  Care and close monitoring is recommended when using this agent in patients presenting diarrhea or at risk of developing diarrhea.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1802, 21700, 'Lenvatinib', 'Peptic Ulcer Perforation', 'Cases of gastrointestinal perforation or fistula have been reported with the use of lenvatinib.  Discontinue the use of lenvatinib in patients who develop gastrointestinal perforation or life-threatening fistula.  Close monitoring should be exercised when using this agent in patients at risk.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1803, 21701, 'Lenvatinib', 'Peptic Ulcer Perforation', 'Cases of gastrointestinal perforation or fistula have been reported with the use of lenvatinib.  Discontinue the use of lenvatinib in patients who develop gastrointestinal perforation or life-threatening fistula.  Close monitoring should be exercised when using this agent in patients at risk.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1804, 21700, 'Lenvatinib', 'Hepatic Insufficiency', 'Hepatic failure, including fatal events have been reported with the use of lenvatinib.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Dose adjustment is needed in patients with severe hepatic impairment.  It is recommended to monitor liver function before initiation of therapy with lenvatinib and regularly thereafter as clinically indicated.  It might be necessary to temporarily withhold the use of lenvatinib and either resume at a reduced dose or discontinue treatment with lenvatinib depending on the severity and persistence of hepatic impairment.  Discontinue treatment with lenvatinib for hepatic failure.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1805, 21701, 'Lenvatinib', 'Hepatic Insufficiency', 'Hepatic failure, including fatal events have been reported with the use of lenvatinib.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Dose adjustment is needed in patients with severe hepatic impairment.  It is recommended to monitor liver function before initiation of therapy with lenvatinib and regularly thereafter as clinically indicated.  It might be necessary to temporarily withhold the use of lenvatinib and either resume at a reduced dose or discontinue treatment with lenvatinib depending on the severity and persistence of hepatic impairment.  Discontinue treatment with lenvatinib for hepatic failure.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1806, 21700, 'Lenvatinib', 'Hypertension', 'The use of lenvatinib may cause hypertension.  It is recommended to control blood pressure prior to treatment with lenvatinib and monitor blood pressure regularly during treatment as medically indicated.  Withhold treatment with lenvatinib for Grade 3 hypertension despite optimal antihypertensive therapy.  If clinically appropriate, resume at a reduced dose when hypertension is controlled and discontinue treatment for hypertension that becomes life-threatening.  Care and close monitoring of blood pressure is recommended.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1807, 21701, 'Lenvatinib', 'Hypertension', 'The use of lenvatinib may cause hypertension.  It is recommended to control blood pressure prior to treatment with lenvatinib and monitor blood pressure regularly during treatment as medically indicated.  Withhold treatment with lenvatinib for Grade 3 hypertension despite optimal antihypertensive therapy.  If clinically appropriate, resume at a reduced dose when hypertension is controlled and discontinue treatment for hypertension that becomes life-threatening.  Care and close monitoring of blood pressure is recommended.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1808, 21700, 'Lenvatinib', 'Hypocalcemia', 'Cases of hypocalcemia have been reported with the use of lenvatinib.  It is recommended to monitor blood calcium levels at least monthly and replace calcium as necessary during treatment and to interrupt and adjust dosing as necessary depending on severity, presence of ECG changes, and persistence of hypocalcemia.  Care should be exercised when using this agent in patients at risk.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1809, 21701, 'Lenvatinib', 'Hypocalcemia', 'Cases of hypocalcemia have been reported with the use of lenvatinib.  It is recommended to monitor blood calcium levels at least monthly and replace calcium as necessary during treatment and to interrupt and adjust dosing as necessary depending on severity, presence of ECG changes, and persistence of hypocalcemia.  Care should be exercised when using this agent in patients at risk.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1810, 21700, 'Lenvatinib', 'Hypothyroidism', 'The use of lenvatinib impairs exogenous thyroid suppression and may cause hypothyroidism.  It is recommended to monitor thyroid function before initiation of, and at least monthly throughout, treatment with lenvatinib.  Care should be taken when using this agent in patients with thyroid dysfunction and treatment of hypothyroidism should be made according to standard medical practice to maintain a euthyroid state.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1811, 21701, 'Lenvatinib', 'Hypothyroidism', 'The use of lenvatinib impairs exogenous thyroid suppression and may cause hypothyroidism.  It is recommended to monitor thyroid function before initiation of, and at least monthly throughout, treatment with lenvatinib.  Care should be taken when using this agent in patients with thyroid dysfunction and treatment of hypothyroidism should be made according to standard medical practice to maintain a euthyroid state.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1812, 21700, 'Lenvatinib', 'Proteinuria', 'Proteinuria has been reported with the use of lenvatinib.  It is recommended to monitor for proteinuria before initiation of, and periodically throughout treatment.  Withhold lenvatinib for >=2 grams of proteinuria/24 hours and resume at a reduced dose when proteinuria is <2 gm/24 hours.  Discontinue lenvatinib for nephrotic syndrome.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1813, 21701, 'Lenvatinib', 'Proteinuria', 'Proteinuria has been reported with the use of lenvatinib.  It is recommended to monitor for proteinuria before initiation of, and periodically throughout treatment.  Withhold lenvatinib for >=2 grams of proteinuria/24 hours and resume at a reduced dose when proteinuria is <2 gm/24 hours.  Discontinue lenvatinib for nephrotic syndrome.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1814, 21700, 'Lenvatinib', 'Long QT Syndrome', 'The use of lenvatinib may cause QT/QTc interval prolongation.  It is recommended to monitor and correct electrolyte abnormalities in all patients and to monitor electrocardiograms in patients with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, or those who are taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics.  Withhold treatment with lenvatinib for the development of QTc interval prolongation greater than 500 ms.  and resume treatment at a reduced dose when QTc prolongation resolves to baseline.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1815, 21701, 'Lenvatinib', 'Long QT Syndrome', 'The use of lenvatinib may cause QT/QTc interval prolongation.  It is recommended to monitor and correct electrolyte abnormalities in all patients and to monitor electrocardiograms in patients with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, or those who are taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics.  Withhold treatment with lenvatinib for the development of QTc interval prolongation greater than 500 ms.  and resume treatment at a reduced dose when QTc prolongation resolves to baseline.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1816, 21700, 'Lenvatinib', 'Kidney Diseases', 'Cases of renal impairment have been reported with the use of lenvatinib.  No dose adjustment is recommended in patients with mild or moderate renal impairment.  Dose adjustment is needed in patients with severe renal impairment.  It might be necessary to temporarily withhold the use of lenvatinib and either resume at a reduced dose or discontinue treatment with lenvatinib depending on the severity and persistence of renal impairment.  Care and close monitoring is recommended when using lenvatinib in patients with end stage renal disease as these patients have not been studied.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1817, 21701, 'Lenvatinib', 'Kidney Diseases', 'Cases of renal impairment have been reported with the use of lenvatinib.  No dose adjustment is recommended in patients with mild or moderate renal impairment.  Dose adjustment is needed in patients with severe renal impairment.  It might be necessary to temporarily withhold the use of lenvatinib and either resume at a reduced dose or discontinue treatment with lenvatinib depending on the severity and persistence of renal impairment.  Care and close monitoring is recommended when using lenvatinib in patients with end stage renal disease as these patients have not been studied.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1818, 21700, 'Lenvatinib', 'Posterior Leukoencephalopathy Syndrome', 'The use of lenvatinib may cause reversible posterior leukoencephalopathy syndrome (RPLS).  Consider this syndrome in any patient presenting with seizures, headache, visual disturbances, confusion or altered mental function.  Confirm the diagnosis of RPLS with MRI and if positive, withhold therapy for RPLS until fully resolved.  Upon resolution, resume at a reduced dose or discontinue treatment depending on the severity and persistence of neurologic symptoms and administer appropriate treatment as clinically indicated.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1819, 21701, 'Lenvatinib', 'Posterior Leukoencephalopathy Syndrome', 'The use of lenvatinib may cause reversible posterior leukoencephalopathy syndrome (RPLS).  Consider this syndrome in any patient presenting with seizures, headache, visual disturbances, confusion or altered mental function.  Confirm the diagnosis of RPLS with MRI and if positive, withhold therapy for RPLS until fully resolved.  Upon resolution, resume at a reduced dose or discontinue treatment depending on the severity and persistence of neurologic symptoms and administer appropriate treatment as clinically indicated.', '2', '"Product Information. Lenvima (lenvatinib)." Eisai Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1820, 21700, 'Lenvatinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1821, 21701, 'Lenvatinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1822, 0, 'Letermovir', 'Liver Diseases', 'The use of letermovir is not recommended for patients with severe (Child-Pugh Class C) hepatic impairment.  No dosage adjustment of letermovir is required for patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.', '3', '"Product Information. Prevymis (letermovir)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1823, 0, 'Letermovir', 'Kidney Diseases', 'Hydroxypropyl betadex present in the intravenous letermovir formulation is mainly eliminated by glomerular filtration.  Decreased elimination of hydroxypropyl betadex has been reported in the literature in patients with severe renal impairment.  Closely monitor serum creatinine levels in patients with CrCl less than 50 mL/min using letermovir injection because accumulation of the intravenous vehicle, hydroxypropyl betadex, could occur.  In patients with CrCl greater than 10 mL/min, no dosage adjustment of letermovir is required based on renal impairment.  The safety of letermovir in patients with end-stage renal disease (CrCl less than 10 mL/min), including patients on dialysis, is unknown.', '2', '"Product Information. Prevymis (letermovir)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1824, 22342, 'Levobunolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1825, 22343, 'Levobunolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1826, 22344, 'Levobunolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1827, 22342, 'Levobunolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1828, 22343, 'Levobunolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1829, 22344, 'Levobunolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1830, 22342, 'Levobunolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1831, 22343, 'Levobunolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1832, 22344, 'Levobunolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1833, 22342, 'Levobunolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1834, 22343, 'Levobunolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1835, 22344, 'Levobunolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1836, 22342, 'Levobunolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1837, 22343, 'Levobunolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1838, 22344, 'Levobunolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1839, 22342, 'Levobunolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1840, 22343, 'Levobunolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1841, 22344, 'Levobunolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1842, 22342, 'Levobunolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1843, 22343, 'Levobunolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1844, 22344, 'Levobunolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1845, 22342, 'Levobunolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1846, 22343, 'Levobunolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1847, 22344, 'Levobunolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1848, 22342, 'Levobunolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1849, 22343, 'Levobunolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1850, 22344, 'Levobunolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1851, 0, 'Antithrombin Alfa', 'Milk Hypersensitivity', 'Treatment with antithrombin recombinant is contraindicated in patients with known hypersensitivity to goat and goat milk proteins.', '3', '"Product Information. ATryn (antithrombin recombinant)." Ovation Pharmaceuticals Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1852, 353, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1853, 534, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1854, 537, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1855, 593, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1856, 695, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1857, 696, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1858, 8507, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1859, 8508, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1860, 9016, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1861, 9017, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1862, 12101, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1863, 12626, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1864, 12628, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1865, 13749, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1866, 13962, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1867, 13974, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1868, 15854, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1869, 16807, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1870, 17565, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1871, 17700, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1872, 23747, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1873, 24942, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1874, 25793, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1875, 25794, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1876, 29025, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1877, 29026, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1878, 29417, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1879, 32142, 'Levamlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995):  1-7|Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996):  921-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1880, 353, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1881, 534, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1882, 537, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1883, 593, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1884, 695, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1885, 696, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1886, 8507, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1887, 8508, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1888, 9016, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1889, 9017, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1890, 12101, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1891, 12626, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1892, 12628, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1893, 13749, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1894, 13962, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1895, 13974, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1896, 15854, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1897, 16807, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1898, 17565, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1899, 17700, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1900, 23747, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1901, 24942, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1902, 25793, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1903, 25794, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1904, 29025, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1905, 29026, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1906, 29417, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1907, 32142, 'Levamlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'Schanzenbacher P, Deeg P, Liebau G, Kochsiek K "Paradoxical angina after nifedipine: angiographic documentation." Am J Cardiol 53 (1984):  345-6|Manga P, Vythilingum "Unstable angina precipitated by nifedipine." S Afr Med J 66 (1984):  144|Sia STB, MacDonald PS, Triester B, et al. "Aggravation of myocardial ischaemia by nifedipine." Med J Aust 142 (1985):  48-50|Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986):  133-6|Lambert CR, Hill JA, Feldman RL, Pepine CJ "Myocardial ischemia during intravenous nicardipine administration." Am J Cardiol 55 (1985):  844-5|Thomassen AR, Bagger JP, Nielsen TT "Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia." Cathet Cardiovasc Diagn 14 (1988):  41-3|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|Furberg CD, Psaty BM, Meyer JV "Nifedipine: dose-related increase in mortality in patients with coronary heart disease." Circulation 92 (1995):  1326-31|Kloner RA "Nifedipine in ischemic heart disease." Circulation 92 (1995):  1074-8|Yusuf S "Calcium antagonists in coronary artery disease and hypertension: time for reevaluation?" Circulation 92 (1995):  1079-82|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Oei SG, Oei SK, Brolmann HAM "Myocardial infarction during nifedipine therapy for preterm labor." N Engl J Med 340 (1999):  154|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1908, 353, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1909, 534, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1910, 537, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1911, 593, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1912, 695, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1913, 696, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1914, 8507, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1915, 8508, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1916, 9016, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1917, 9017, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1918, 12101, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1919, 12626, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1920, 12628, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1921, 13749, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1922, 13962, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1923, 13974, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1924, 15854, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1925, 16807, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1926, 17565, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1927, 17700, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1928, 23747, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1929, 24942, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1930, 25793, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1931, 25794, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1932, 29025, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1933, 29026, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1934, 29417, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1935, 32142, 'Levamlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'Echizen H, Eichelbaum M "Clinical pharmacokinetics of verapamil, nifedipine and diltiazem." Clin Pharmacokinet 11 (1986):  425-49|Saracheck NS, London RL, Matulewicz TJ, et al. "Diltiazem and granulomatous hepatitis." Gastroenterology 88 (1985):  1260-2|Shallcross H, Padley SP, Glynn MJ, Gibbs DD "Fatal renal and hepatic toxicity after treatment with diltiazem." Br Med J 295 (1987):  1256-7|Colombo G, Zucchella G, Planca E, Grieco A "Intravenous diltiazem in the treatment of unstable angina: a study of efficacy and tolerance." Clin Ther 9 (1987):  536-47|Toft E, Vyberg M, Therkelsen K "Diltiazem-induced granulomatous hepatitis." Histopathology 18 (1991):  474-5|Abramson M, Littlejohn GO "Hepatic reactions to nifedipine." Med J Aust 142 (1985):  47-8|Toner M, White A, Moriarty J, Clancy L "Allergic urticarial eruption, leukocytosis and abnormal liver function tests following nifedipine administration." Chest 93 (1988):  1320-1|Babany G, Uzzan F, Larrey D, et al. "Alcoholic-like liver lesions induced by nifedipine." J Hepatol 9 (1989):  252-5|Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981):  490-1|Somogyi A, Albrecht M, Kliems G, et al. "Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis." Br J Clin Pharmacol 12 (1981):  51-60|Woodcock BG, Rietbrock I, Vohringer HF, Rietbrock N "Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships." Clin Pharmacol Ther 29 (1981):  27-34|Woodcock BG, Rietbrock N "Verapamil bioavailability and dosage in liver disease." Br J Clin Pharmacol 13 (1982):  240-1|Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982):  612-3|Stehle G, Buss J, Eibach J, et al. "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990):  1079|Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986):  610-11|Guarascio P, D''Amato C, Sette P, et al. "Liver damage from verapamil." Br Med J 288 (1984):  362-3|Dow RJ, Graham DJM "A reveiw of the human metabolism and pharmacokinetics of nicardipine hydrochloride." Br J Clin Pharmacol 22 (1986):  s195-202|McAllister RG Jr, Hamann SR, Blouin RA "Pharmacokinetics of calcium-entry blockers." Am J Cardiol 55 (1985):  b30-40|Kates RE "Calcium antagonists: pharmacokinetic properties." Drugs 25 (1983):  113-24|Finucci GF, Padrini R, Piovan D, et al. "Verapamil pharmacokinetics and liver function in patients with cirrhosis." Int J Clin Pharmacol Res 8 (1988):  123-6|Giacomini KM, Massoud N, Wong FM, Giacomini JC "Decreased binding of verapamil to plasma proteins in patients with liver disease." J Cardiovasc Pharmacol 6 (1984):  924-8|Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ "The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine." Clin Pharmacol Ther 47 (1990):  463-9|Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJ "The metabolism of nicardipine hydrochloride in healthy male volunteers." Xenobiotica 16 (1986):  341-9|Benet LZ "Pharmacokinetics and metabolism of bepridil." Am J Cardiol 55 (1985):  c8-13|Kurosawa S, Kurosawa N, Owada E, et al. "Pharmacokinetics of diltiazem in patients with liver cirrhosis." Int J Clin Pharmacol Res 10 (1990):  311-8|Elliott HL, Meredith PA "The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine." Postgrad Med J 67 (1991):  s20-3|Stopher DA, Beresford AP, Macrae PV, Humphrey MJ "The metabolism and pharmacokinetics of amlodipine in humans and animals." J Cardiovasc Pharmacol 12 (1988):  s55-9|Kleinbloesem CH, van Harten J, Wilson JP, et al. "Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration." Clin Pharmacol Ther 40 (1986):  21-8|Raemsch KD, Sommer J "Pharmacokinetics and metabolism of nifedipine." Hypertension 5 (1983):  18-24|Ramsch KD, Graefe KH, Scherling D, et al. "Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine." Am J Nephrol 6 (1986):  73-80|Challenor VF, Waller DG, Renwick AG, et al. "The trans-hepatic extraction of nifedipine." Br J Clin Pharmacol 24 (1987):  473-7|Dunselman PH, Edgar B "Felodipine clinical pharmacokinetics." Clin Pharmacokinet 21 (1991):  418-30|Regardh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C "Pharmacokinetics of felodipine in patients with liver disease." Eur J Clin Pharmacol 36 (1989):  473-9|Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E "Pharmacokinetics of isradipine in patients with chronic liver disease." Eur J Clin Pharmacol 38 (1990):  599-603|Tse FL, Jaffe JM "Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man." Eur J Clin Pharmacol 32 (1987):  361-5|Graham D, Dow R, Hall D, Alexander O, Mroszczak E, Freedman A "The metabolism and pharmacokinetics of nicardipine hydrochloride in man." Br J Clin Pharmacol 20 (1985):  s23-8|Gengo FM, Fagan SC, Krol G, Bernhard H "Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls." Br J Clin Pharmacol 23 (1987):  47-53|Meredith P, Elliott H "Clinical pharmacokinetics of amlodipine." Clin Pharmacokinet 22 (1992):  22-31|"Product Information. Norvasc (amlodipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Vascor (bepridil)." McNeil Pharmaceutical  (2002):|"Product Information. Cardizem (diltiazem)." Hoechst Marion Roussel  (2002):|"Product Information. Plendil (felodipine)." Merck & Co., Inc  (2002):|"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc  (2002):|"Product Information. Procardia (nifedipine)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Nimotop (nimodipine)." Bayer  (2002):|"Product Information. Calan (verapamil)." Searle  (2001):|Johnson KE, Balderston SM, Pieper JA, Mann DE, Reiter MJ "Electrophysiologic effects of verapamil metabolites in the isolated heart." J Cardiovasc Pharmacol 17 (1991):  830-7|"Product Information. Dynacirc (isradipine)." Sandoz Pharmaceuticals Corporation|Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994):  485-6|Traverse JH, Swenson LJ, Mcbride JW "Acute hepatic injury after treatment with diltiazem." Am Heart J 127 (1994):  1636-9|Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E "Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man." Arzneimittelforschung 38 (1988):  1105-10|"Product Information. Sular (nisoldipine)." Astra-Zeneca Pharmaceuticals  (2001):|Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999):  1447-57|"Product Information. Conjupri (levamlodipine)." CSPC Ouyi Pharmaceutical Co, Ltd  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1936, 7612, 'Leuprolide', 'Cardiovascular Diseases', 'Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with the use of GnRH agonists such as leuprolide, and triptorelin.  Cardiovascular risk factors should be evaluated carefully before treatment initiation.  Patients should be monitored for symptoms and signs suggestive of development or cardiovascular disease and should be managed according to current clinical practice.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):|"Product Information. Trelstar (triptorelin)." Pharmacia and Upjohn  (2001):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1937, 22101, 'Leuprolide', 'Cardiovascular Diseases', 'Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with the use of GnRH agonists such as leuprolide, and triptorelin.  Cardiovascular risk factors should be evaluated carefully before treatment initiation.  Patients should be monitored for symptoms and signs suggestive of development or cardiovascular disease and should be managed according to current clinical practice.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):|"Product Information. Trelstar (triptorelin)." Pharmacia and Upjohn  (2001):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1938, 22125, 'Leuprolide', 'Cardiovascular Diseases', 'Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with the use of GnRH agonists such as leuprolide, and triptorelin.  Cardiovascular risk factors should be evaluated carefully before treatment initiation.  Patients should be monitored for symptoms and signs suggestive of development or cardiovascular disease and should be managed according to current clinical practice.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):|"Product Information. Trelstar (triptorelin)." Pharmacia and Upjohn  (2001):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1939, 22126, 'Leuprolide', 'Cardiovascular Diseases', 'Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with the use of GnRH agonists such as leuprolide, and triptorelin.  Cardiovascular risk factors should be evaluated carefully before treatment initiation.  Patients should be monitored for symptoms and signs suggestive of development or cardiovascular disease and should be managed according to current clinical practice.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):|"Product Information. Trelstar (triptorelin)." Pharmacia and Upjohn  (2001):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1940, 7612, 'Leuprolide', 'Diabetes Mellitus', 'Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists such as leuprolide and triptorelin.  Caution is advised in patients with diabetes as treatment with these agents may risk glycemic control.  Monitor blood glucose and/or HbA1c periodically in patients receiving treatment.', '2', '"Product Information. Trelstar (triptorelin)." Pharmacia and Upjohn  (2001):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1941, 22101, 'Leuprolide', 'Diabetes Mellitus', 'Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists such as leuprolide and triptorelin.  Caution is advised in patients with diabetes as treatment with these agents may risk glycemic control.  Monitor blood glucose and/or HbA1c periodically in patients receiving treatment.', '2', '"Product Information. Trelstar (triptorelin)." Pharmacia and Upjohn  (2001):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1942, 22125, 'Leuprolide', 'Diabetes Mellitus', 'Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists such as leuprolide and triptorelin.  Caution is advised in patients with diabetes as treatment with these agents may risk glycemic control.  Monitor blood glucose and/or HbA1c periodically in patients receiving treatment.', '2', '"Product Information. Trelstar (triptorelin)." Pharmacia and Upjohn  (2001):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1943, 22126, 'Leuprolide', 'Diabetes Mellitus', 'Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists such as leuprolide and triptorelin.  Caution is advised in patients with diabetes as treatment with these agents may risk glycemic control.  Monitor blood glucose and/or HbA1c periodically in patients receiving treatment.', '2', '"Product Information. Trelstar (triptorelin)." Pharmacia and Upjohn  (2001):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1944, 7612, 'Leuprolide', 'Long QT Syndrome', 'Androgen deprivation therapy may prolong the QT/QTc interval.  Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval.  Consider periodic monitoring of EKG and electrolytes.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1945, 22101, 'Leuprolide', 'Long QT Syndrome', 'Androgen deprivation therapy may prolong the QT/QTc interval.  Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval.  Consider periodic monitoring of EKG and electrolytes.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1946, 22125, 'Leuprolide', 'Long QT Syndrome', 'Androgen deprivation therapy may prolong the QT/QTc interval.  Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval.  Consider periodic monitoring of EKG and electrolytes.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1947, 22126, 'Leuprolide', 'Long QT Syndrome', 'Androgen deprivation therapy may prolong the QT/QTc interval.  Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval.  Consider periodic monitoring of EKG and electrolytes.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1948, 7612, 'Leuprolide', 'Bone Diseases, Metabolic', 'Decreased bone density has been reported in men who have had orchiectomy or who have been treated with a GnRH agonist analog as leuprolide.  It can be anticipated that long periods of medical castration in men will have effects on bone density.  Bone density loss may not be reversible.  Therapy with leuprolide should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids).  Therapy beyond six months with gonadotropin-releasing hormone analogs is not recommended for patients with major risk factors for decreased bone mineral content.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1949, 22101, 'Leuprolide', 'Bone Diseases, Metabolic', 'Decreased bone density has been reported in men who have had orchiectomy or who have been treated with a GnRH agonist analog as leuprolide.  It can be anticipated that long periods of medical castration in men will have effects on bone density.  Bone density loss may not be reversible.  Therapy with leuprolide should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids).  Therapy beyond six months with gonadotropin-releasing hormone analogs is not recommended for patients with major risk factors for decreased bone mineral content.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1950, 22125, 'Leuprolide', 'Bone Diseases, Metabolic', 'Decreased bone density has been reported in men who have had orchiectomy or who have been treated with a GnRH agonist analog as leuprolide.  It can be anticipated that long periods of medical castration in men will have effects on bone density.  Bone density loss may not be reversible.  Therapy with leuprolide should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids).  Therapy beyond six months with gonadotropin-releasing hormone analogs is not recommended for patients with major risk factors for decreased bone mineral content.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1951, 22126, 'Leuprolide', 'Bone Diseases, Metabolic', 'Decreased bone density has been reported in men who have had orchiectomy or who have been treated with a GnRH agonist analog as leuprolide.  It can be anticipated that long periods of medical castration in men will have effects on bone density.  Bone density loss may not be reversible.  Therapy with leuprolide should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids).  Therapy beyond six months with gonadotropin-releasing hormone analogs is not recommended for patients with major risk factors for decreased bone mineral content.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1952, 7612, 'Leuprolide', 'Seizures', 'Convulsions have been observed in patients taking leuprolide, including patients who have a history of seizures, epilepsy, or brain disorders, and in those taking medications associated with convulsions.  Convulsions have also been reported in patients without any of these conditions.  Caution is advised in patients with a history of seizures.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1953, 22101, 'Leuprolide', 'Seizures', 'Convulsions have been observed in patients taking leuprolide, including patients who have a history of seizures, epilepsy, or brain disorders, and in those taking medications associated with convulsions.  Convulsions have also been reported in patients without any of these conditions.  Caution is advised in patients with a history of seizures.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1954, 22125, 'Leuprolide', 'Seizures', 'Convulsions have been observed in patients taking leuprolide, including patients who have a history of seizures, epilepsy, or brain disorders, and in those taking medications associated with convulsions.  Convulsions have also been reported in patients without any of these conditions.  Caution is advised in patients with a history of seizures.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1955, 22126, 'Leuprolide', 'Seizures', 'Convulsions have been observed in patients taking leuprolide, including patients who have a history of seizures, epilepsy, or brain disorders, and in those taking medications associated with convulsions.  Convulsions have also been reported in patients without any of these conditions.  Caution is advised in patients with a history of seizures.', '2', '"Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):|"Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1956, 154, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1957, 375, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1958, 400, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1959, 7207, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1960, 7242, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1961, 7243, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1962, 7261, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1963, 7270, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1964, 12654, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1965, 12655, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1966, 13769, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1967, 13786, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1968, 16227, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1969, 21090, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1970, 21717, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1971, 21735, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1972, 21754, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1973, 21756, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1974, 21767, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1975, 21768, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1976, 21769, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1977, 21836, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1978, 22609, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1979, 22881, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1980, 24258, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1981, 24259, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1982, 28607, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1983, 28608, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1984, 29825, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1985, 31862, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1986, 33460, 'Levocetirizine', 'Kidney Diseases', 'The use of levocetirizine is contraindicated in patients with end-stage renal disease (CrCl < 10 mL/min), and in patients undergoing hemodialysis.  It is also contraindicated in pediatric patients (ages 6 months to 11 years) with impaired renal function.  Levocetirizine is excreted by the kidneys and the risk of adverse reactions is greater in patients with renal impairment.  Caution is advised.', '3', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1987, 154, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1988, 375, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1989, 400, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1990, 7207, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1991, 7242, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1992, 7243, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1993, 7261, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1994, 7270, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1995, 12654, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1996, 12655, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1997, 13769, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1998, 13786, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1999, 16227, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2000, 21090, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
